...FH. Gen-Probe acquired Elucigene FH20, which has CE Mark approval, through its 2009 acquisition of Tepnel Life Sciences plc...

...FH. Gen-Probe acquired Elucigene FH20, which has CE Mark approval, through its 2009 acquisition of Tepnel Life Sciences plc...

...an important test for the company. Gen-Probe got the product through its 2009 acquisition of Tepnel Life Sciences plc...

...December. Gen-Probe acquired Elucigene FH20, which has CE Mark approval, through its 2009 acquisition of Tepnel Life Sciences plc...

...December. Gen-Probe acquired Elucigene FH20, which has CE Mark approval, through its 2009 acquisition of Tepnel Life Sciences plc...

...December. Gen-Probe acquired Elucigene FH20, which has CE Mark approval, through its 2009 acquisition of Tepnel Life Sciences plc...

...products, including its Elucigene range of kits, which Gen-Probe gained through its 2009 acquisition of Tepnel Life Sciences plc...

...to focus on human molecular diagnostic opportunities. Gen-Probe gained the business through its acquisition of Tepnel Life Sciences plc...

...lowered its FY09 GAAP EPS estimate to $1.72-$1.90 from $1.80-$2.05 to reflect its acquisitions of Tepnel Life Sciences plc...

...so far this year," said portfolio manager Andy Smith. "By the time Genentech, CV Therapeutics, Tepnel...
...8% of the fund, which does not go back in the market on one day." Tepnel Life Sciences plc...